Diabetes Devices Market to Sustain Solid Growth This Decade

The worldwide diabetes devices market will be a stable moneymaker this decade.

Straits Research predicts the sector to expand 6.62% annually through 2030 to reach $49.25 billion, a 78% increase from its 2021 value ($27.66 billion). North America and Europe are the two most important markets for diabetes devices. With an expected market value of $18.94 billion by 2030, North America is expected to be the largest market for diabetes devices. 

The market’s main growth drivers are the increasing focus on diabetes care and technological advancements in product innovation. There is also an increasing number of initiatives being conducted by governments and charity groups to raise diabetes awareness.  
The Ministry of Health and Family Welfare, the WHO Country Office for India, and other partners, for example, have established mDiabetes, a mobile health program. This public health effort aims to raise awareness about diabetes early detection and treatment. Similarly, the World Health Organization (WHO) and IDF collaborate to prevent and control diabetes while also ensuring a high quality of life for individuals worldwide.
 
The WHO Diabetes Program aims to prevent type 2 diabetes, reduce complications, and improve diabetes patients’ quality of life. To increase diabetes prevention and control, NGOs and governments are developing norms and standards, raising knowledge about diabetes prevention, and supporting surveillance. As a result, the growing number of diabetes awareness initiatives is likely to contribute to diabetes diagnosis, hence increasing the usage of diabetic devices.
 
Demand for these devices is being driven by introducing high-end insulin pumps and pens and technological developments in diabetic devices. Leading manufacturers focus on technological advancements and introduce innovative products to gain a significant market share. Novo Nordisk, for example, launched the NovoPen Echo, a new instrument on the market, in January 2014. This is the first gadget in the United States with memory and half-unit dosing features.
 
In August 2016, Medtronic introduced the MiniMed 630G system in the United States, an integrated insulin pump with continuous glucose monitoring (CGM) technology that delivers better glucose management than multiple injections while avoiding hypoglycemia. As a result, market growth is fueled by technological advances and product improvements.
 
The COVID-19 outbreak provided a severe barrier to healthcare delivery, with severe consequences for diabetes treatment. The closure of routine outpatient clinics has hampered diabetes treatment, reduced inpatient capacity, personnel shortages, medicine shortages, costly medicine, delayed care-seeking, limited self-care practice, transportation issues, and undiagnosed cases/events. 
 
Diabetes device sales, on the other hand, have risen as a result of consumers’ constant monitoring of their diabetes status to avoid infection with the COVID-19 virus, which is particularly sensitive to people with diabetes. The overall diabetic devices market growth was limited during the first phase of the pandemic due to severe supply chain limitations.
 
For the global diabetic devices market, the post-pandemic period will be critical. Manufacturing operations may impede the recovery process, affecting market dynamics and product prices. Also, other end-user sectors, suppliers, and vendors may be unable to meet customer demand due to limited manufacturing, support operations, labor shortages, and other constraints. Overall, the global diabetes devices market recovery will be difficult.